Trial ID or NCT#





This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Official Title

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Andrei Iagaru
Associate Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center
Sanjiv Sam Gambhir, MD, PhD
Robert Herfkens
Professor of Radiology (General Radiology)
Shreyas Vasanawala, MD/PhD
Professor of Radiology (Pediatric Radiology)
Erik Mittra
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine

Contact us to find out if this trial is right for you.


Risa Jiron
(650) 736-1598